Panbela Therapeutics, Inc.
DelistedCIK 1029125fmd_1ACKRZQVQRE1S6W4X5GMJRCTQMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2024, 52 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | – | – | – | – | – | – | – | – | – |
| Cost of revenue | 1 | – | – | – | – | – | – | – | – | – |
| Gross profit | 1 | – | – | – | – | – | – | – | – | – |
| Research and development | 2 | 3 | 3 | 3 | 2 | 2 | 3 | 5 | 28 | 21 |
| Total operating expenses | – | – | – | – | – | – | – | – | – | – |
| Operating income | (3) | (5) | (5) | (6) | (4) | (4) | (6) | (10) | (34) | (26) |
| Interest expense | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | – | – | – | – | – | – | 0 | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | (0) | (5) | (2) | (2) | 1 | (1) | (1) | 0 |
| Income before taxes | (4) | (6) | (5) | (11) | (6) | (7) | (5) | (11) | (35) | (25) |
| Income tax expense | (0) | (1) | (0) | (1) | (0) | (0) | (0) | (0) | (0) | (0) |
| Net income from continuing operations | (0) | (5) | (5) | (10) | (6) | (6) | (5) | (10) | (35) | (25) |
| Net income | (4) | (5) | (5) | (10) | (6) | (6) | (5) | (10) | (35) | (25) |